S100. Efficacy and Safety of Brexanolone IV Across Phase 2/3 Studies: A First-In-Class GABAA Receptor Positive Allosteric Modulator for Postpartum Depression

O46. SAGE-217 a First in Class GABAA Receptor Positive Allosteric Modulator in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Phase 2 Placebo-Controlled Trial

Biological Psychiatry ◽

10.1016/j.biopsych.2018.02.333 ◽

2018 ◽

Vol 83 (9) ◽

pp. S127-S128

Author(s):

Handan Gunduz-Bruce ◽

Christopher Silber ◽

Anthony Rothschild ◽

Robert Riesenberg ◽

Abdul Sankoh ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Gabaa Receptor ◽

Controlled Trial ◽

Allosteric Modulator ◽

Phase 2 ◽

Major Depressive ◽

Double Blind

Zuranolone—An Investigational Oral Neuroactive Steroid and Positive Allosteric Modulator of GABA Type A Receptors for Postpartum Depression and Major Depressive Disorder

US Neurology ◽

10.17925/usn.2020.16.2.81 ◽

2020 ◽

Vol 16 (2) ◽

pp. 81

Author(s):

Handan Gunduz-Bruce ◽

Keyword(s):

Major Depressive Disorder ◽

Postpartum Depression ◽

Depressive Disorder ◽

Type A ◽

Allosteric Modulator ◽

Neuroactive Steroid ◽

Major Depressive

SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies

Clinical Pharmacokinetics ◽

10.1007/s40262-019-00801-0 ◽

2019 ◽

Vol 59 (1) ◽

pp. 111-120 ◽

Cited By ~ 6

Author(s):

Ethan Hoffmann ◽

George G. Nomikos ◽

Inder Kaul ◽

Shane Raines ◽

Jeff Wald ◽

...

Keyword(s):

Clinical Pharmacology ◽

Phase I ◽

Gabaa Receptor ◽

Dose Finding ◽

Allosteric Modulator ◽

Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator

Neuropharmacology ◽

10.1016/j.neuropharm.2020.108333 ◽

2020 ◽

Vol 181 ◽

pp. 108333

Author(s):

Alison L. Althaus ◽

Michael A. Ackley ◽

Gabriel M. Belfort ◽

Steven M. Gee ◽

Jing Dai ◽

...

Keyword(s):

Gabaa Receptor ◽

Allosteric Modulator ◽

Neuroactive Steroid ◽

A Translational Approach to Evaluate the Efficacy and Safety of the Novel AMPA Receptor Positive Allosteric Modulator Org 26576 in Adult Attention-Deficit/Hyperactivity Disorder

Biological Psychiatry ◽

10.1016/j.biopsych.2012.05.012 ◽

2012 ◽

Vol 72 (11) ◽

pp. 971-977 ◽

Cited By ~ 24

Author(s):

Lenard A. Adler ◽

René A. Kroon ◽

Mark Stein ◽

Mohammed Shahid ◽

Frank I. Tarazi ◽

...

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Ampa Receptor ◽

Attention Deficit ◽

Allosteric Modulator ◽

The Novel ◽

Efficacy And Safety ◽

Hyperactivity Disorder ◽

Translational Approach

A novel positive allosteric modulator of the GABAA receptor: the action of (+)-ROD188

British Journal of Pharmacology ◽

10.1038/sj.bjp.0703558 ◽

2000 ◽

Vol 131 (4) ◽

pp. 843-850 ◽

Cited By ~ 9

Author(s):

Urs Thomet ◽

Roland Baur ◽

Rodolphe Razet ◽

Robert H Dodd ◽

Roman Furtmüller ◽

...

Keyword(s):

Gabaa Receptor ◽

Allosteric Modulator ◽

Effects of the α2/α3-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats

Behavioural Pharmacology ◽

10.1097/fbp.0000000000000464 ◽

2019 ◽

Vol 30 (5) ◽

pp. 452-461 ◽

Cited By ~ 5

Author(s):

Megan J. Moerke ◽

Guanguan Li ◽

Lalit K. Golani ◽

James Cook ◽

S. Stevens Negus

Keyword(s):

Gabaa Receptor ◽

Allosteric Modulator ◽

Subtype Selective

PMH76 - PATIENT REPORTED MEASURES OF DEPRESSIVE SYMPTOMS AND FATIGUE IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

Value in Health ◽

10.1016/j.jval.2018.09.2887 ◽

2018 ◽

Vol 21 ◽

pp. S287

Author(s):

V. Bonthapally ◽

E. Suthoff ◽

P. Hodgkins ◽

H. Gunduz-Bruce ◽

R. Lasser ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Symptoms ◽

Depressive Disorder ◽

Controlled Trial ◽

Allosteric Modulator ◽

Phase 2 ◽

Major Depressive ◽

Patient Reported ◽

Patient Reported Measures

Faculty Opinions recommendation of The α6 GABAA Receptor Positive Allosteric Modulator DK-I-56-1 Reduces Tic-Related Behaviors in Mouse Models of Tourette Syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739477984.793582579 ◽

2021 ◽

Author(s):

Kevin J Black ◽

Keisuke Ueda

Keyword(s):

Gabaa Receptor ◽

Tourette Syndrome ◽

Mouse Models ◽

Allosteric Modulator ◽

Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865

British Journal of Pharmacology ◽

10.1111/bph.14119 ◽

2018 ◽

Vol 175 (4) ◽

pp. 708-725 ◽

Cited By ~ 24

Author(s):

Sarah A Nickolls ◽

Rachel Gurrell ◽

Guido van Amerongen ◽

Juha Kammonen ◽

Lishuang Cao ◽

...

Keyword(s):

Gabaa Receptor ◽

Clinical Profile ◽

Allosteric Modulator ◽

The Novel ◽